Expanding the Gene Expression Profiling of Drug Transporters and Drug-Metabolizing Enzymes to Include the Upper Female Reproductive Tract
Open Access
- 21 May 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 629
Abstract
Background/Objectives: With the ongoing efforts in supporting the discovery of novel targeted drug delivery systems for the upper region of the female reproductive tract (FRT), it is imperative to understand the local drug disposition pathways. We aim to obtain a comprehensive profile of the drug transporters and drug-metabolizing enzymes in the human ectocervix, uterus, and fallopian tubes, as these factors may substantially influence mucosal penetration, tissue exposure, drug disposition, and the risk of drug–drug interactions. Methods: Gene expression of 12 drug transporters and 21 drug-metabolizing enzymes was quantified using RT-qPCR. Protein expression of highly expressed transporters was assessed using immunohistochemistry (IHC). Results: Among the 12 transporters analyzed, the efflux transporters P-gp, BCRP, and MRP4 exhibited the highest expression across the ectocervix, endometrium, myometrium, and fallopian tubes, with P-gp consistently showing the greatest abundance in all evaluated FRT tissues. Expression of these transporters was significantly higher (6–17×) in myometrium compared with ectocervix. IHC demonstrated strong localization of P-gp, BCRP, and MRP4 to epithelial layers facing the lumen, as well as to stromal and vascular endothelial cells. For drug-metabolizing enzymes, all 21 phase I and II enzymes were detectable across the FRT, and 15 were expressed at comparatively higher levels across all tissue types. These included CYP1A1, CYP1B1, CYP2B6, CYP2C8, CYP2C19, CYP3A4, UGT1A1, UGT1A3, UGT1A4, UGT1A7, UGT1A8, UGT1A10, UGT2B4, UGT2B15, and UGT2B17. Conclusions: The gene expression and localization data obtained from this work may improve our understanding of drug disposition in the FRT, which will inform selection, design, and optimization of drugs intended for targeted delivery within the FRT.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-040478)
- U.S. Food and Drug Administration (HHSF223201810188C)
This publication has 33 references indexed in Scilit:
- Drug delivery strategies for management of women’s health issues in the upper genital tractAdvanced Drug Delivery Reviews, 2021
- Review of Complex Generic Drugs Delivered Through the Female Reproductive Tract: The Current Competitive Landscape and Emerging Role of Physiologically Based Pharmacokinetic Modeling to Support Development and Regulatory DecisionsThe Journal of Clinical Pharmacology, 2020
- Sexually transmitted diseases and infertilityAmerican Journal of Obstetrics and Gynecology, 2017
- Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryJournal of Controlled Release, 2015
- Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionThe Journal of Clinical Pharmacology, 2013
- Augmented epithelial multidrug resistance–associated protein 4 expression in peritoneal endometriosis: regulation by lipoxin A4Fertility and Sterility, 2013
- CYP1B1 and hormone-induced cancerCancer Letters, 2012
- Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNAMetabolism, 2007
- Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)Biochemical Pharmacology, 2005
- Transporters and drug therapy: Implications for drug disposition and diseaseClinical Pharmacology & Therapeutics, 2005